Who makes doxycycline carragenate tablet?

doxycycline carragenate tablet is developed by Pfizer.

What development phase is doxycycline carragenate tablet in?

doxycycline carragenate tablet is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

doxycycline carragenate tablet

Pfizer · FDA-approved active Small molecule Quality 2/100

Doxycycline carragenate tablet, marketed by Pfizer, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	doxycycline carragenate tablet
Sponsor	Pfizer
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

doxycycline carragenate tablet CI brief — competitive landscape report
doxycycline carragenate tablet updates RSS · CI watch RSS
Pfizer portfolio CI